Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Tsai, Ying-NanYing-NanTsaiWu, Jia-LingJia-LingWuTseng, Cheng-HaoCheng-HaoTsengChen, Tzu-HawTzu-HawChenWu, Yi-LingYi-LingWuCHIEH-CHANG CHENYU-JEN FANGYang, Tzeng-HueyTzeng-HueyYangNguyen, Mindie HMindie HNguyenJAW-TOWN LINHsu, Yao-ChunYao-ChunHsu2024-03-282024-03-282024-0122872728https://www.scopus.com/record/display.uri?eid=2-s2.0-85181663143&doi=10.3350%2fcmh.2023.0194&origin=inward&txGid=4c38ffb5760f838c2072cc7858fdd7cdhttps://scholars.lib.ntu.edu.tw/handle/123456789/641508Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR).enAntiviral treatment; Chronic hepatitis B; Finite nucleos(t)ide analog therapy; Hepatitis B core-related antigenHepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessationjournal article10.3350/cmh.2023.0194380925512-s2.0-85181663143https://api.elsevier.com/content/abstract/scopus_id/85181663143